We propose to develop an innovative therapeutic strategy that uses this export of BRCA1 from nucleus to cytoplasm to transiently convert BRCA1-proficient GBM cells into functionally BRCA1-deficient cells and thereby render them susceptible to PARP inhibitor–induced cell killing (Figure 1). Here, BRCA1 is linked to glioblastoma.